Catalogue
Research peptides2 specifications

CJC-1295 NO DAC

COA on request

CJC-1295 No DAC is a synthetic growth-hormone-releasing hormone analogue supplied without the Drug Affinity Complex modification. Multiple specifications are grouped on one page.

Wholesale quote requiredPrice confirmed by sales
Choose specification
Selected SKU
CND5
Pack
5 mg x 10 vials
Status
Available for inquiry

No payment is taken online. Sales confirms availability, documentation, shipping, and commercial terms.

Purity>99%Estimated delivery: within one week after the order is placed.
COA is available on request

COA files are available in the document library; additional batch-specific documentation can be requested with your inquiry. Each batch is tested with HPLC purity analysis (≥99%). For MSDS or detailed storage protocols, please contact our sales team.

Order formatOne box accepted
DeliveryWithin one week after order
ShippingShipping and duties included
DocumentationCOA available on request

Research effects

As a growth hormone-releasing hormone (GHRH) analogue, CJC-1295 NO DAC (the version without the drug affinity complex, also known as Mod GRF 1-29) demonstrates significant potential in stimulating endogenous growth hormone secretion.

Efficacy

Users commonly report increased muscle strength, reduced body fat, and improvements in sleep quality and skin elasticity. Compared to the DAC-containing version, the NO DAC version has a shorter half-life, allowing it to better mimic the natural pulsatile rhythm of growth hormone secretion, which is considered more physiological and may help avoid risks associated with persistently elevated growth hormone levels. In clinical applications, this class of peptides has been studied for improving age-related decline in growth hormone levels, helping to maintain muscle mass, bone density, and overall vitality.

Research mechanism

CJC-1295 NO DAC acts by binding to and activating the growth hormone-releasing hormone receptor (GHRH-R) on the anterior pituitary gland. The peptide contains a modified amino acid sequence that confers resistance to protease degradation, significantly extending its in vivo activity duration. Upon receptor binding, it activates the downstream cAMP/PKA signaling pathway, stimulating growth hormone synthesis and release. Notably, the short-acting nature of the NO DAC version prevents sustained, plateau-like elevation of growth hormone levels, instead maintaining a pulsatile release pattern that more closely aligns with the body's circadian rhythm. This pulsatile secretion is essential for maintaining normal physiological feedback regulation, effectively avoiding excessive elevation of insulin-like growth factor-1 (IGF-1) that can result from continuously high growth hormone levels, thereby better maintaining glucose metabolic balance while enhancing anabolic signaling.

Product details

Key identity and handling information for the selected research material.

Material identity

The label 'No DAC' is sometimes used inconsistently. Confirm exact sequence, terminal form, molecular mass, and absence of the DAC moiety.

Storage guidance

Store unopened material in its original sealed packaging, protected from light, moisture, and repeated temperature changes. Follow the product label and batch document for the exact storage temperature. After opening or preparation, use only a validated laboratory storage protocol.

Quality review

Report a quality concern within 14 days of delivery with the order, batch details and available photos.

Resolution

When a quality claim is approved, choose a full refund or replacement shipment.

24/7 WhatsApp contact

Sales support remains available for product, documentation and wholesale inquiry follow-up.

CND55 mg x 10 vials